Solvonis Therapeutics announced positive preclinical pharmacokinetic data for its SVN-002 program, repurposing Johnson & Johnson's esketamine to treat moderate to severe alcohol use disorder. The data showed comparable drug exposure via sublingual and buccal delivery to the approved intranasal method, supporting a regulatory pathway that could speed development. The company plans to engage the FDA on toxicology requirements before submitting for Phase 2b trial approval in the US. This approach targets a large market with an estimated 15 million affected adults and aims for a capital-efficient development process.
The global brain implants market, valued at $7.10 billion in 2025, is projected to grow at a CAGR of 9.99% to reach $18.39 billion by 2035. Growth is fueled by advances in neurotechnology, including deep brain stimulation and brain-computer interface...
SpaceX has landed major data center contracts with Anthropic, Google, and Reflection, potentially generating over $76 billion in revenue through 2029. These deals highlight SpaceX's expanding role beyond space exploration into cloud infrastructure. T...
Affluent crypto investors are concentrating their holdings in Bitcoin, Ethereum, and XRP as market volatility drives a risk-off approach. These top cryptocurrencies dominate portfolios due to their liquidity and brand strength, while many altcoins re...
Figma is evolving beyond a traditional design software into a comprehensive AI-driven product creation platform. This shift challenges its existing seat-based revenue model but opens new opportunities through AI credits and platform expansion. The co...
Chainlink experienced its largest network growth days of 2026 by adding 6,182 new wallets over June 25-26, signaling rising adoption despite a weak crypto market. This surge in new users came even as LINK's price faced downward pressure near multi-mo...
